InMed Pharmaceuticals Inc.
For the period ended Jun 30, 2025. Filed Sep 23, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Sep 23, 2025
INM$15.56+17.8%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| June 30, | June 30, | |
|---|---|---|
| 2025 | 2024 | |
| $ | $ | |
| ASSETS | ||
| Current | ||
| Cash and cash equivalents | 11,075,871 | 6,571,610 |
| Short-term investments | 43,384 | 43,064 |
| Accounts receivable (less provision for credit losses of $2,424 and $nil as of June 30, 2025 and 2024, respectively) | 465,104 | 352,838 |
| Inventories, net | 961,173 | 1,244,324 |
| Prepaids and other current assets | 321,747 | 477,749 |
| Total current assets | 12,867,279 | 8,689,585 |
| Non-Current | ||
| Property, equipment and ROU assets, net | 992,199 | 1,249,999 |
| Intangible assets, net | 1,620,562 | 1,783,198 |
| Other assets | 100,000 | 100,000 |
| Total Assets | 15,580,040 | 11,822,782 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| Current | ||
| Accounts payable and accrued liabilities | 1,404,283 | 1,654,011 |
| Current portion of lease obligations | 435,507 | 317,797 |
| Total current liabilities | 1,839,790 | 1,971,808 |
| Non-current | ||
| Lease obligations, net of current portion | 305,755 | 644,865 |
| Total Liabilities | 2,145,545 | 2,616,673 |
| Commitments and Contingencies (Note 12) | ||
| Shareholders’ Equity | ||
| Common shares, no par value, unlimited authorized shares: 2,002,186 and 445,908 as of June 30, 2025 and 2024, respectively, issued and outstanding | 91,221,174 | 82,784,400 |
| Additional paid-in capital | 39,322,644 | 35,368,899 |
| Accumulated deficit | (117,237,892) | (109,075,759) |
| Accumulated other comprehensive income | 128,569 | 128,569 |
| Total Shareholders’ Equity | 13,434,495 | 9,206,109 |
| Total Liabilities and Shareholders’ Equity | 15,580,040 | 11,822,782 |
| Related Party Transactions (Note 13) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.